NASDAQ:GERN - Geron Stock Price, Forecast & News

Geron trades on the NASDAQ under the ticker symbol "GERN."

Geron Co. (NASDAQ:GERN) posted its earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.06. The biopharmaceutical company had revenue of $0.13 million for the quarter, compared to the consensus estimate of $0.10 million. Geron had a negative return on equity of 29.22% and a negative net margin of 7,044.88%. During the same quarter in the prior year, the business earned $0.24 earnings per share. View Geron's Earnings History.

Geron is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Geron.

5 brokerages have issued 1-year price objectives for Geron's stock. Their forecasts range from $3.00 to $4.00. On average, they expect Geron's share price to reach $3.80 in the next year. This suggests a possible upside of 151.7% from the stock's current price. View Analyst Price Targets for Geron.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Geron.

Press coverage about GERN stock has trended very negative on Sunday, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Geron earned a media sentiment score of -3.7 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Geron.

Some companies that are related to Geron include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Seattle Genetics (SGEN), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Geron investors own include Novavax (NVAX), TransEnterix (TRXC), Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), Puma Biotechnology (PBYI), Dynavax Technologies (DVAX), Horizon Therapeutics (HZNP), Anavex Life Sciences (AVXL), Bristol-Myers Squibb (BMY) and Exelixis (EXEL).

Geron's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include State Street Corp (1.76%), SG Americas Securities LLC (0.19%), Rhumbline Advisers (0.15%), California State Teachers Retirement System (0.14%), Barclays PLC (0.07%) and Creative Planning (0.06%). Company insiders that own Geron stock include Melissa Kelly Behrs, Robert J Spiegel and Stephen Rosenfield. View Institutional Ownership Trends for Geron.

GERN stock was sold by a variety of institutional investors in the last quarter, including Metropolitan Life Insurance Co NY, State Street Corp, Commonwealth Equity Services LLC and Creative Planning. View Insider Buying and Selling for Geron.

GERN stock was acquired by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, Squarepoint Ops LLC, Rhumbline Advisers, Barclays PLC, Summit X LLC and California State Teachers Retirement System. View Insider Buying and Selling for Geron.

Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GERN stock can currently be purchased for approximately $1.51.

Geron has a market capitalization of $301.67 million and generates $1.07 million in revenue each year. The biopharmaceutical company earns $-27,020,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. Geron employs 17 workers across the globe.View Additional Information About Geron.

The official website for Geron is http://www.geron.com/.

Geron's mailing address is 149 COMMONWEALTH DRIVE SUITE 2070, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-473-7700 or via email at [email protected]